ROTARIXTM is celebrating its 1st birthday
Abstract
It’s been one year since launch and ROTARIXTM is celebrating.
Data from a recent study announced at ESPID (European
Society for Paediatric Infectious Diseases) showed that
ROTARIXTM, the first oral rotavirus vaccine available to children in South Africa, protects against up to 96% of severe rotavirus gastroenteritis (RVGE) cases and prevents up to 100% of hospitalisations due to rotavirus-induced gastroenteritis in a European setting.
Data from a recent study announced at ESPID (European
Society for Paediatric Infectious Diseases) showed that
ROTARIXTM, the first oral rotavirus vaccine available to children in South Africa, protects against up to 96% of severe rotavirus gastroenteritis (RVGE) cases and prevents up to 100% of hospitalisations due to rotavirus-induced gastroenteritis in a European setting.